Is Hydrus FDA approved?
Hydrus Microstent was approved by the FDA in August 2018 for use in conjunction with cataract surgery in the United States. In the UK, Canada, Australia, Singapore, and Germany, the MIGS device is indicated for primary open-angle glaucoma in conjunction with cataract surgery or as a stand-alone procedure. What are the success rates of Hydrus microstent? A five-year clinical trial found glaucoma patients who had cataract surgery and a Hydrus microstent implant had a 66% chance of no longer needing glaucoma drops, compared to 46% in the group who underwent cataract surgery alone.Expected recovery for combined Hydrus and cataract surgery is nearly the same as the recovery for cataract surgery alone. Studies have found the Hydrus to be very safe for those who qualify for the surgery.